Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergence
Bullen, G.; Galson, J. D.; Villar, P.; Moreels, L.; Ledsgaard, L.; Mattiuzzo, G.; Hall, G.; Bentley, E. M.; Masters, E. W.; Tang, D.; Millett, S.; Tongue, D.; Brown, R.; Diamantopoulos, I.; Parthiban, K.; Tebbutt, C.; Leah, R.; Chaitanya, K.; Pazeraitis, D.; Surade, S. B.; Ashiru, O.; Crippa, L.; Cowan, R.; Bowler, M. W.; Campbell, J. I.; Lee, W.-Y. J.; Carr, M. D.; Matthews, D.; Pfeffer, P.; Hufton, S. E.; Sawmynaden, K.; Osbourn, J.; McCafferty, J.; Karatt-Vellatt, A.
Show abstract
Passive immunisation using monoclonal antibodies will play a vital role in the fight against COVID-19. Until now, the majority of anti-SARS-CoV-2 antibody discovery efforts have relied on screening B cells of patients in the convalescent phase. Here, we describe deep-mining of the antibody repertoires of hospitalised COVID-19 patients using a combination of phage display technology and B cell receptor (BCR) repertoire sequencing to isolate neutralising antibodies and gain insights into the early antibody response. This comprehensive discovery approach has yielded potent neutralising antibodies with distinct mechanisms of action, including the identification of a novel non-ACE2 receptor blocking antibody that is not expected to be affected by any of the major viral variants reported. The study highlighted the presence of potent neutralising antibodies with near germline sequences within both the IgG and IgM pools at early stages of infection. Furthermore, we highlight a highly convergent antibody response with the same sequences occurring both within this study group and also within the responses described in previously published anti-SARS-CoV-2 studies.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability 97%
- Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model 96%
- Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants 96%
Similar papers in this journal
- Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities 96%
- Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination 96%
- HIV Envelope Trimer-Elicited Autologous Neutralizing Antibodies Bind a Region Overlapping the N332 Glycan Supersite 96%
Similar papers in this journal
- Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody 97%
- Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages 97%
- SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma 96%
Similar papers in this journal
- Opsonization by non-neutralizing antibodies can confer protection to SARS-CoV-2 despite Spike-dependent modulation of phagocytosis 96%
- Regulatory approved monoclonal antibodies contain framework mutations predicted from human antibody repertoires 96%
- Pox-AbDab: the Orthopoxvirus Antibody Database 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.